Last rites for the first glitazone
FDA withdraws approval for NDA for Pfizer's Rezulin (troglitazone), a notice in the Jan. 10 Federal Register states. Pfizer withdrew the NDA for the diabetes drug after the product was pulled from the market in 2000 following 90 cases of acute liver damage, including 63 deaths (1"The Pink Sheet" March 27, 2000, p. 4)...
You may also be interested in...
AstraZeneca's proposed Exanta risk management plan is not sufficient to alleviate liver toxicity concerns with the anticoagulant, FDA's Cardiovascular & Renal Drugs Advisory Committee said
The removal of Warner-Lambert's Rezulin will boost sales of the two newer antidiabetic "glitazones," SmithKline Beecham/Bristol-Myers Squibb's Avandia and Lilly/Takeda's Actos.
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.